Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 69 current clinical trials in our China register. 44 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Adebrelimab, Aflibercept Intravitreous and Albumin-Bound Paclitaxel /nab-Paclitaxel. The most-studied condition is Peripheral T Cell Lymphoma.

ClinicalTrials.gov trials by status

Recruiting4464%
Not yet open2435%
Active, closed11%

Trials by phase

Not applicable2130%
Observational1826%
Phase EARLY_PHASE11116%
Phase 21014%
Phase 134%
Phase 423%
Phase 323%
Phase 2/323%

Clinical trials sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

69 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
CLL-1 CAR-NK Cells for Relapsed/Refractory AML NCT06307054 · Relapsed Adult AML, Refractory AML	Phase 1	Recruiting	2024-04	China
BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. NCT06598722 · ClinicalTrials.gov ↗ · Lymphoblastic Lymphoma, Adult, Lymphoblastic Leukemia, Acute T-cell	Phase 2	Recruiting	2024-08	China
Allo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR) NCT07253129 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Observational	Recruiting	2025-12	China
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC NCT07434518 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC) Drug: Adebrelimab	Observational	Recruiting	2026-01	China
Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma NCT07162012 · ClinicalTrials.gov ↗ · NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCL	Phase EARLY_PHASE1	Recruiting	2025-09	China
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC NCT06251115 · ClinicalTrials.gov ↗ · Liver Cancer	Not applicable	Recruiting	2024-01	China
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR NCT07470996 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Observational	Recruiting	2025-10	China
Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction Surgery NCT07601282 · ClinicalTrials.gov ↗ · Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI)	Observational	Recruiting	2024-12	China
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients NCT06832774 · ClinicalTrials.gov ↗ · Prostate Cancer Metastatic Disease Drugs: GnRHa, Rezvilutamide	Phase 2	Recruiting	2025-08	China
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification NCT06612944 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes, Adult	Phase 2	Recruiting	2024-11	China
Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors NCT07439120 · ClinicalTrials.gov ↗ · Urothelial Carcinoma (UC)	Phase EARLY_PHASE1	Recruiting	2026-04	China
Effectiveness of Perioperative Percutaneous Acupuncture on Postoperative Sleep Disturbances and Chronic Pain in Patients Undergoing Video-Assisted Thoracoscopic Lung Cancer Resection: A Prospective, Randomized, Single-Blind, Superiority Controlled Trial NCT07662733 · ClinicalTrials.gov ↗ · Postoperative Sleep Disturbances, Chronic Post-surgical Pain	Not applicable	Recruiting	2025-06	China
Subthalamic Nucleus-Targeted Transcranial Temporal Interference Stimulation for Motor and Non-Motor Symptoms in Parkinson's Disease NCT07625540 · ClinicalTrials.gov ↗ · Parkinson's Disease (PD)	Not applicable	Recruiting	2026-05	China
Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2 NCT06920199 · ClinicalTrials.gov ↗ · cGVHD Drug: Aldesleukin	Phase EARLY_PHASE1	Recruiting	2025-06	China
Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis NCT06307080 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Not applicable	Recruiting	2023-10	China
Antibiotic Prophylaxis for Ureteroscopy With a Negative Pressure Suction Sheath NCT07246967 · ClinicalTrials.gov ↗ · Urolithiasis, Antibiotics	Not applicable	Recruiting	2026-02	China
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease NCT06002581 · ClinicalTrials.gov ↗ · Parkinson's Disease	Not applicable	Recruiting	2023-09	China
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors NCT05831033 · ClinicalTrials.gov ↗ · Solid Tumor	Phase EARLY_PHASE1	Recruiting	2023-05	China
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer NCT06532617 · ClinicalTrials.gov ↗ · Pancreatic Neoplasms	Phase 2	Recruiting	2024-09	China
Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07601737 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Head & Neck Cancer Drugs: Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin, Cisplatin	Phase 2	Recruiting	2026-04	China
Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients NCT07053358 · ClinicalTrials.gov ↗ · Neovascular Age-related Macular Degeneration	Phase EARLY_PHASE1	Recruiting	2025-07	China
Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression NCT05465252 · ClinicalTrials.gov ↗ · Age-Related Macular Degeneration	Not applicable	Recruiting	2025-10	China
T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR NCT07353840 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Observational	Recruiting	2026-01	China
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement NCT06111612 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia	Observational	Recruiting	2024-01	China
Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer NCT06515587 · ClinicalTrials.gov ↗ · PDAC	Not applicable	Recruiting	2024-08	China
Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy NCT07414758 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma Drug: Golidocitinib	Phase 3	Recruiting	2026-02	China
Evaluation of Vulnerability of Carotid Plaques and Prediction of Cardio-Cerebrovascular Event Using Ultrasonic Imaging NCT06473272 · ClinicalTrials.gov ↗ · Carotid Plaque, Ischemic Stroke, Cardiovascular Events	Observational	Recruiting	2024-07	China
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention NCT06686108 · ClinicalTrials.gov ↗ · T-cell Acute Lymphoblastic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Relapse	Phase 2	Recruiting	2024-10	China
Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease NCT07588854 · ClinicalTrials.gov ↗ · Chronic Liver Disease (CLD), Liver Fibrosis	Observational	Recruiting	2026-05	China
Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients NCT07362927 · ClinicalTrials.gov ↗ · Diabetic Macular Edema (DME)	Phase EARLY_PHASE1	Recruiting	2026-03	China
Total Infectome Characterization of Eye Infections NCT06775808 · ClinicalTrials.gov ↗ · Eye Infections, Diagnosis	Observational	Recruiting	2024-12	China
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML. NCT06483906 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Recruiting	2024-07	China
Bile Omics for Diagnosing Indeterminate Biliary Strictures NCT07007832 · ClinicalTrials.gov ↗ · Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer	Observational	Recruiting	2024-01	China
Radical Resection With Contralateral Lymph Node Dissection for Clinical N3 NSCLC NCT07003490 · ClinicalTrials.gov ↗ · NSCLC, Non Small Cell Lung Cancer	Not applicable	Recruiting	2025-01	China
A Study of LX107 Gene Therapy in AIPL1-IRD Patients NCT07063030 · ClinicalTrials.gov ↗ · Retinal Dystrophy	Phase EARLY_PHASE1	Recruiting	2025-07	China
A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET NCT06592989 · ClinicalTrials.gov ↗ · Pancreatic Neuroendocrine Neoplasm, Sorafenib, Gefitinib	Observational	Recruiting	2024-09	China
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma NCT07389616 · ClinicalTrials.gov ↗ · Peripheral T Cell Lymphoma	Phase 2/3	Recruiting	2026-02	China
An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa NCT06936787 · ClinicalTrials.gov ↗ · Retinitis Pigmentosa	Phase 1	Recruiting	2025-04	China
Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS) NCT05814952 · ClinicalTrials.gov ↗ · X-linked Retinoschisis	Not applicable	Recruiting	2022-12	China
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors NCT07570745 · ClinicalTrials.gov ↗ · Graft-Versus-Host Disease(GVHD), Bone Marrow Transplantation	Phase 2	Recruiting	2026-05	China
Comparing Super Pulse Fiber Thulium Laser and Holmium Laser for Ureteral Stone Fragmentation During Ureteroscopy NCT06667557 · ClinicalTrials.gov ↗ · Kidney Calculi	Observational	Recruiting	2025-01	China
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma NCT06652243 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase EARLY_PHASE1	Recruiting	2024-11	China
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) NCT05536102 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Recruiting	2022-09	China
PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer. NCT07167264 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Not applicable	Recruiting	2025-07	China
Evaluate the Efficacy of Radiofrequency Ablation/Vertebroplasty with or Without SBRT for Treating Painful Spinal Vertebral Metastases NCT06756087 · ClinicalTrials.gov ↗ · Spinal Metastases, Local Control, Pain Cancer	Not applicable	Not yet open	2025-01	China
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) NCT07365371 · ClinicalTrials.gov ↗ · Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD) Drug: Aflibercept Intravitreous	Phase 4	Not yet open	2026-01	China
Efficacy of S.T.O.P®KIT in Retarding Axial Length Growth in Children With Low Hyperopia NCT07401511 · ClinicalTrials.gov ↗ · Children, Hyperopia	Not applicable	Not yet open	2026-02	China
Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy NCT06568445 · ClinicalTrials.gov ↗ · Bronchial Asthma	Phase 4	Not yet open	2024-08	China
Application of Quantitative Hemorrhage Detection in Fetomaternal Hemorrhage Syndrome for the Diagnosis of Hemolytic Disease of the Newborn NCT07371520 · ClinicalTrials.gov ↗ · Hemolytic Disease of the Newborn	Observational	Not yet open	2026-03	China
Observation of the Natural Course of Age-related Macular Degeneration NCT05418231 · ClinicalTrials.gov ↗ · Dry Age-related Macular Degeneration, Macular Degeneration, Dry	Observational	Not yet open	2022-07	China
Compound Granules of Hedyotis Diffusa for Chronic Atrophic Gastritis NCT07391800 · ClinicalTrials.gov ↗ · Chronic Atrophic Gastritis With Hyperplasia (Diagnosis)	Not applicable	Not yet open	2026-01	China
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients NCT07142863 · ClinicalTrials.gov ↗ · Osteosarcoma, Neoadjuvant Therapy, Neoadjuvant Chemotherapy	Phase 2	Not yet open	2025-08	China
PSMA-PET/MRI-Ultrasound Multimodal Fusion Navigation for Da Vinci Robot-Assisted Radical Prostatectomy: A Randomized Controlled Trial NCT07272317 · ClinicalTrials.gov ↗ · Prostate Cancer	Not applicable	Not yet open	2025-12	China
Postoperative Sleep Quality and Pain of Patients After Video-Assisted Thoracoscopic Surgery NCT06633432 · ClinicalTrials.gov ↗ · Sleep Disorder	Not applicable	Not yet open	2024-12	China
A Clinical Study on Alleviating Hemorrhoids-related Symptoms of Pelvic Radiation Therapy NCT07175584 · ClinicalTrials.gov ↗ · Hemorrhoidal Disease, Cervical Cancer Radiation Complications	Not applicable	Not yet open	2025-09	China
Clinical Study of FB1001 in Patients NCT06506305 · ClinicalTrials.gov ↗ · Optic Neuropathy, NAION - Non-Arteritic Ischemic Optic Neuropathy, APAC - Acute Primary Angle Closure	Phase 1	Not yet open	2024-08	China
A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy NCT07117175 · ClinicalTrials.gov ↗ · Immunology, Hematologic Malignancies, CAR-NK	Phase EARLY_PHASE1	Not yet open	2025-09	China
Safety, Tolerability, and Accuracy of a Hydrogel-Based Wearable Dynamic Intraocular Pressure Sensor in Healthy Adults NCT07770178 · ClinicalTrials.gov ↗ · Intraocular Pressure	Not applicable	Not yet open	2026-08	China
Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy NCT07353398 · ClinicalTrials.gov ↗ · Heterozygous Familial Hypercholesterolemia	Phase EARLY_PHASE1	Not yet open	2026-03	China
Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control NCT07330180 · ClinicalTrials.gov ↗ · Myopia, Myopia, Progressive	Not applicable	Not yet open	2026-01	China
AI vs. Physician for Anti-VEGF Decision-Making: An RCT NCT07328776 · ClinicalTrials.gov ↗ · DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration	Not applicable	Not yet open	2026-05	China
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors NCT07463313 · ClinicalTrials.gov ↗ · Thymoma and Thymic Carcinoma	Phase 2/3	Not yet open	2026-03	China
VAH vs VA in Newly Diagnosed Elderly AML NCT07469046 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)	Phase 3	Not yet open	2026-04	China
Prognostic Study of Prostate Cancer Via Dynamic Change of PSA in Peritoneal Drainage Fluid After Radical Prostatectomy NCT06608225 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, Prostate-Specific Antigen	Observational	Not yet open	2024-12	China
Visual Function and Exercise in Glaucoma Patients NCT07824232 · ClinicalTrials.gov ↗ · Glaucoma, Exercise	Observational	Not yet open	2026-09	China
TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor NCT06619886 · ClinicalTrials.gov ↗ · Solid Tumor, Adult, Lung Adenocarcinoma, Pancreas Cancer	Phase EARLY_PHASE1	Not yet open	2024-09	China
Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy NCT06707974 · ClinicalTrials.gov ↗ · Prostatic Neoplasms, ctDNA	Observational	Not yet open	2024-12	China
Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis NCT07328074 · ClinicalTrials.gov ↗ · Thymic Epithelial Tumor, Thymoma, Thymic Carcinoma	Observational	Not yet open	2026-02	China
Quick Yielding Modified Short-Distance Fenestration Technique for the Treatment of Complex Aortic Arch Diseases: a Multicenter Single-Arm Objective Performance Criteria Trial(QYM-Tech Study) NCT06639243 · ClinicalTrials.gov ↗ · Thoracic Aortic Dissection, Thoracic Aortic Aneurysm (true Aneurysm), Thoracic Pseudoaneurysm	Not applicable	Active, closed	2024-01	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

13 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Adebrelimab1 Aflibercept Intravitreous1 Albumin-Bound Paclitaxel /nab-Paclitaxel1 Aldesleukin1 Carboplatin1 Cisplatin1 Docetaxel1 GnRHa1 Golidocitinib1 Nimotuzumab1 Pembrolizumab1 Rezvilutamide1 Tislelizumab1

Conditions in Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

115 conditions

Peripheral T Cell Lymphoma5 Pancreatic Cancer3 Neoadjuvant Therapy2 Acute Myeloid Leukemia2 Prostatic Neoplasms2Relapsed Adult AML1Refractory AML1Lymphoblastic Lymphoma, Adult1Lymphoblastic Leukemia, Acute T-cell1Small Cell Lung Cancer (SCLC)1Spinal Metastases1Local Control1Pain Cancer1NK/T-cell Lymphoma1Peripheral T-cell Lymphoma (PTCL)1DLBCL1Polypoidal Choroidal Vasculopathy (PCV)1Neovascular Age Related Macular Degeneration (AMD)1Liver Cancer1 Children1Hyperopia1Pelvic Organ Prolapse (POP)1Stress Urinary Incontinence (SUI)1Prostate Cancer Metastatic Disease1

By trial register

Register	Trials	Recruiting
Clinical trials in China	69	44

A trial with sites in more than one country appears in each of those registers.

Questions about Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials

How many clinical trials does Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine sponsor?

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is the lead sponsor of 69 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials recruiting?

Yes. 44 of its 69 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine testing?

Its current trials name 13 drugs and biologicals as interventions. The most frequent are Adebrelimab (1), Aflibercept Intravitreous (1), Albumin-Bound Paclitaxel /nab-Paclitaxel (1), Aldesleukin (1) and Carboplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine clinical trials